Last updated: February 15, 2026
Product Overview
NDC 51672-4074 corresponds to Tucatinib (brand name Tukysa), a kinase inhibitor approved for HER2-positive metastatic breast cancer, including cases with brain metastases. Approved by the FDA in April 2020, Tucatinib was developed by Seattle Genetics and AstraZeneca.
Market Landscape
The global breast cancer therapeutics market was valued at approximately $16 billion in 2022, with targeted therapies comprising a significant share. HER2-positive treatments represent a noteworthy segment within this, estimated at 20-25% of breast cancer cases, translating into a potential patient pool of around 300,000 in the US alone.
Competitive Environment
Tucatinib faces competition from existing HER2-targeted therapies such as trastuzumab, pertuzumab, and ado-trastuzumab emtansine (Kadcyla). The drug's unique selling points include efficacy in brain metastases and an oral administration route, which provides advantages over intravenous options.
Pricing Foundations
The current wholesale acquisition cost (WAC) for Tucatinib is approximately $15,500 per month, equating roughly to $186,000 annually based on current dosing regimens—generally 300 mg twice daily. This pricing reflects the drug's novelty, competitive positioning, and the high reimbursement environment for oncology treatments.
Price Trends and Projections
-
Current Pricing (2023):
WAC around $15,500/month, or approximately $186,000/year.
-
Market Penetration:
Approximately 10-15% of eligible patients in the US have prescriptions, driven by physician adoption, payer coverage, and patient access programs.
-
Future Price Trajectories:
Price stabilization is anticipated through 2025. Given high unmet need in brain metastases and the drug's differentiators, pricing may hold steady; however, with increased competition or biosimilar development, especially if patent expirations occur or new entrants gain approval, discounts could emerge.
-
Cost-effectiveness and Payer Negotiations:
Payers may push for discounts or value-based agreements, potentially reducing net prices by 10-20%. Manufacturers might respond with patient assistance programs or tiered copayments.
Market Expansion Opportunities
Potential expansion includes:
- Off-label use in HER2-positive gastric cancers.
- Combination therapies with other agents.
- Accelerated approvals in other countries, notably Europe and Asia.
Regulatory and Policy Factors
Pricing in Europe depends on individual national health agencies (e.g., NICE in the UK) and may vary significantly. International markets typically see lower prices compared to the US, with discounts ranging from 20-50%.
Key Risks Affecting Price and Market Share
- Development of competitors with superior efficacy or safety profiles.
- Patent litigation or expiry projections set for 2030.
- Regulatory hurdles in emerging markets.
Summary
Tucatinib's market remains emergent with stable pricing around $15,500/month in the US. Market share growth hinges on physician adoption, reimbursement policies, and competition dynamics. Price reductions are possible through payer negotiations; expansion into additional indications or markets could sustain or increase revenue.
Key Takeaways
- Tucatinib's current US price is approximately $186,000 annually.
- It addresses a niche with unmet needs, notably brain metastases.
- Market share is limited by competition but driven by clinical advantages.
- Price stability is probable in the near term; long-term trends depend on competitive and regulatory developments.
- International pricing varies, with substantial discounts outside the US.
FAQs
1. What are the main competitors to Tucatinib?
Main competitors include trastuzumab, pertuzumab, and T-DM1, which are established HER2-targeted therapies. New entrants or biosimilars could also challenge Tucatinib's market share.
2. How does the efficacy of Tucatinib compare with existing treatments?
Clinical trials demonstrate superior progression-free survival and overall response rates in HER2-positive metastatic breast cancer with brain metastases compared to older therapies, especially in patients with central nervous system involvement.
3. Are there plans to expand Tucatinib's indications?
Yes. Ongoing trials are exploring combination therapies and potential use in other HER2-positive cancers, including gastric and colorectal malignancies.
4. What factors could influence Tucatinib's future price?
Patent expiry, competition from biosimilars, clinical trial outcomes, and negotiations with payers can all impact future pricing.
5. How accessible is Tucatinib across different markets?
In the US, access depends on insurance coverage and patient assistance programs. International access varies, with lower prices in European and Asian markets due to different pricing regulations and health policies.
Citations
[1] U.S. Food and Drug Administration. "Tucatinib (Tukysa) Approval." 2020.
[2] EvaluatePharma. "Global Oncology Market Data." 2022.
[3] Medical Economics. "HER2-positive Breast Cancer Market Overview." 2022.
[4] IQVIA. "Pharmaceutical Pricing and Reimbursement Data." 2023.
